Related references
Note: Only part of the references are listed.Dietary supplementation of n-3 PUFA reduces weight gain and improves postprandial lipaemia and the associated inflammatory response in the obese JCR:LA-cp rat
Z. Hassanali et al.
DIABETES OBESITY & METABOLISM (2010)
Cannabinoids and the gut: New developments and emerging concepts
Angelo A. Izzo et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Effect of Rimonabant on the High-Triglyceride/Low-HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat The ADAGIO-Lipids Trial
Jean-Pierre Despres et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding
Angelo A. Izzo et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
The CB1 Antagonist Rimonabant Decreases Insulin Hypersecretion in Rat Pancreatic Islets
Lisa Getty-Kaushik et al.
OBESITY (2009)
Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease
Toshiyuki Hayashi et al.
ATHEROSCLEROSIS (2008)
Intestinal lipid transport and chylomicron production: Possible links to exacerbated atherogenesis in a rodent model of the metabolic syndrome
Donna F. Vine et al.
ATHEROSCLEROSIS SUPPLEMENTS (2008)
Rimonabant in rats with a metabolic syndrome: good news after the depression
V. Di Marzo et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Regulation of C/EBPδ-dependent transactivation by histone deacetylases in intestinal epithelial cells
Naomie Turgeon et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
Aldosterone and TGF-β1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells
Wei Huang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)
Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats
P. Janiak et al.
KIDNEY INTERNATIONAL (2007)
Overeating by young obesity-prone and lean rats caused by tastes associated with low energy foods
W. David Pierce et al.
OBESITY (2007)
Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community
Ravi Dhingra et al.
CIRCULATION (2007)
Chylomicron and apoB48 metabolism in the JCR:LA corpulent rat, a model for the metabolic syndrome
R. Mangat et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
Rimonabant: Just an Antiobesity drug? Current evidence on its pleiotropic effects
Maurizio Bifulco et al.
MOLECULAR PHARMACOLOGY (2007)
Increased insulin sensitivity and reduced micro and macro vascular disease induced by 2-deoxy-D-glucose during metabolic syndrome in obese JCR: LA-cp rats
J. C. Russell et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
The link between abdominal obesity, metabolic syndrome and cardiovascular disease
S. A. Ritchie et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2007)
Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat:: Increased atherogenicity for the metabolic syndrome
D. F. Vine et al.
ATHEROSCLEROSIS (2007)
PAI-1 as a target in kidney disease
Yufeng Huang et al.
CURRENT DRUG TARGETS (2007)
Synergistic effects of conjugated linoleic acid and chromium picolinate improve vascular function and renal pathophysiology in the insulin-resistant JCR : LA-cp rat
S. D. Proctor et al.
DIABETES OBESITY & METABOLISM (2007)
Rimonabant: endocannabinoid inhibition for the metabolic syndrome
A. S. Wierzbicki
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2006)
Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis
James C. Russell et al.
CARDIOVASCULAR PATHOLOGY (2006)
Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo
A. Schepers et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
How many sites of action for endocannabinoids to control energy metabolism?
U Pagotto et al.
INTERNATIONAL JOURNAL OF OBESITY (2006)
Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in. nonobese Type 2 diabetic patients
K Takebayashi et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2006)
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: A randomized controlled trial
F Pi-Sunyer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Insulin-sensitizing and cardiovascular effects of the sodium-hydrogen exchange inhibitor, cariporide, in the JCR -: LA-cp rat and db/db mouse
JC Russell et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2005)
Rimonabant: The first therapeutically relevant cannabinoid antagonist
MAM Carai et al.
LIFE SCIENCES (2005)
Anorectics on trial: A half century of federal regulation of prescription appetite suppressants
E Colman
ANNALS OF INTERNAL MEDICINE (2005)
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity
D Osei-Hyiaman et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:: 1-year experience from the RIO-Europe study
LF Van Gaal et al.
LANCET (2005)
Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice
YL Liu et al.
INTERNATIONAL JOURNAL OF OBESITY (2005)
The anti-obesity effect of rimonabant is associated with an improved serum lipid profile
B Poirier et al.
DIABETES OBESITY & METABOLISM (2005)
Chronic vasopeptidase inhibition normalizes diabetic endothelial dysfunction
S Schäfer et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy
SD Proctor et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Genes, environment and Oji-Cree type 2 diabetes
RA Hegele et al.
CLINICAL BIOCHEMISTRY (2003)
Animal models of insulin resistance and cardiovascular disease: some therapeutic approaches using the JCR : LA-cp rat
DN Brindley et al.
DIABETES OBESITY & METABOLISM (2002)
Global burden of cardiovascular diseases - Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization
S Yusuf et al.
CIRCULATION (2001)
Effects of LY117018 and the estrogen analogue, 17 alpha-ethinylestradiol, on vascular reactivity, platelet aggregation, and lipid metabolism in the insulin-resistant JCR : LA-cp male rat: Role of nitric oxide
JC Russell et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2001)
Vascular wall function in insulin-resistant JCR:LA-cp rats:: Role of male and female sex
SF O'Brien et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2000)
Recent progress in obesity pharmacotherapy
DH Ryan
CURRENT OPINION IN GASTROENTEROLOGY (2000)
Share Paper
